Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting

Ads

You May Also Like

Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2

Data in 50 patients with recurrent metastatic carcinoma of the cervix demonstrates a 52% ...

Rexahn Announces $5 Million Registered Direct Offering

ROCKVILLE, Md., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today ...